ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

B-27 Finds Improved CR For Taxotere Prior To Surgery

November 28, 2003

Survey Finds 70 Percent of Oncologists Prescribe Avastin Off-Label For Ovarian Cancer

August 30, 2013

Protocols Approved By NCI

April 30, 2004

HCFA Sees Applications For DRGs And Research

September 27, 1985

Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden

July 26, 2013

ACCC Planning Session Considers Community Impact

August 31, 1979